Using TEE to Evaluate the Effect of Levosimendan on Patients With ARDS Associated With RVD During MV
Transesophageal Echocardiography, Acute Respiratory Distress Syndrome, Right Ventricular Dysfunction
About this trial
This is an interventional treatment trial for Transesophageal Echocardiography
Eligibility Criteria
Inclusion Criteria: Patients who agree to participate in this clinical trial and sign informed consent Age 18-80 years old, gender unlimited Patients with ARDS(According to the diagnostic criteria of ARDS in Berlin 2012) requiring mechanical ventilation; Acute right ventricular dysfunction due to ARDS Exclusion Criteria: Pregnant or lactating women; Chronic cardiac insufficiency, pulmonary hypertension and/or right ventricular enlargement caused by chronic cardiopulmonary disease, cardiogenic shock or after major cardiac surgery before ARDS; right ventricular myocardial infarction; Uncorrected hypotension, hypoxemia and hypercapnia, or acid-base balance disturbance Mechanical ventilation driving pressure >=18cmH2O before randomization Rapid arrhythmia; pericardial tamponade; Pulmonary embolism; severe renal insufficiency; severe liver insufficiency; Failure to sign informed consent; known allergy to the test drug and control drug; Patients who have participated in other clinical trials within 30 days
Sites / Locations
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
treatment group A
treatment group B
intravenously injected levosimendan 12.5mg with 5% glucose injection 50ml configuration at 2ml/h for 24h
treatment group B: control group with 5% glucose injection 2ml/h for 24h